All GLG News Analyses Filed Under: Ophthalmology

Watershed Intraocular Lens: The Light Adjsutable Lens (Calhoun Vision)

November 19, 2009

Analysis by: GLG Expert Contributor

Analysis of:Pilot trial for toric correction with light-adjustable lens yields promising early results | ophthalmologytimes.modernmedicine.com

SInce years ophthalmologist await the approval of the LAL Light adjustable lens (calhoun VIsion) as it will represent a watershed in intraocular lens technology. 

Ozurdex (Allergan) Uses Billing Structure That May Prevent Acceptance

November 9, 2009

Analysis by: GLG Expert Contributor

Analysis of:Dexamethasone implant a first for macular edema after retinal vein occlusion | ophthalmologytimes.modernmedicine.com

Ozurdex (Allergan) is now on the market and available for ophthalmologists to treat patients with retinal vascular occlusions (RVO).While the technology and treatment may be sound, there may be significant hurdles to overcome from a billing standpoint.Ozurdex may follow the same fate as Lucentis (Genetech).  It must compete with a much cheaper drug which has comparable efficacy.

Andrew DahlPresident Ophthalmology Consultants

Lumigan X EU Committee Recomendation

October 27, 2009

Analysis of:EU committee backs marketing approval of Lumigan | www.pharmabiz.com

The Committee for Medicinal Products for Human Use (CHMP) of the European Union has recommended granting a Marketing Authorization for a new version of Allergan's Lumigan (bimatoprost ophthalmic solution). This new version will be marketed as Lumigan-X after approval. Lumigan X offers Allergan a new formulation to compete against generic versions of its glaucoma drug Lumigan after patent protection for Lumigan expires shortly.There will be very limited demand for Lumigan-X.

NO BRAINER: Genentech Prefers to Promote Lucentis over Avastin for Wet ARMD

October 7, 2009

Analysis by: GLG Expert Contributor

Analysis of:Genentech revisits plan for Avastin | www.sfgate.com

It does not require a lot of ophthalmic and business savy to understand why a company rather promote a drug that costs more than 20 times more to treat the same medical condition.

Steve RubinsteinOptometristSound Shore Vision Care

Contact Lens Nirvana: Hyperpermeable One Day

October 2, 2009

Analysis of:Hobby assists Irish strategy | www.opticianonline.net

 This article describes resources being put into place to mass produce the first commercially available silicon hydrogel one day disposable contact lens in the USA by Johnson & Johnson's Vistakon division.

Mark PackerClinical Associate Professor of OphthalmologyOREGON HEALTH & SCIENCE UNIVERSITY - CC

Tecnis Multifocal Outperforms Competitors

September 20, 2009

Analysis of:Summary of Safety and Effectiveness Data (FDA) | www.fda.gov

The US Clinical Investigation of the Tecnis Multifocal demonstrated 88% complete freedom from glasses at 6 months, and 95% satisfaction at one year.  A comparable study of the ReStor lenses, with both 3 and 4 diopter adds, demonstrated 76% freedom from glasses at 4 - 6 months.  Despite a one line lower performance at intermediate range for the Tecnis the overall results favor its adoption for providing presbyopia correction after cataract surgery.

Mark PackerClinical Associate Professor of OphthalmologyOREGON HEALTH & SCIENCE UNIVERSITY - CC

AMO Grows Portfolio, Potential with Acquisition of Accommodating Lens Implant

September 3, 2009

Analysis of:Abbott to Acquire Visiogen, Expanding Vision Care Portfolio | www.abbott.com

 It was announced today that Abbot Labs intends to acquire Visiogen (Santa Ana, CA) for $400 million in cash.  Earlier this year Abbott acquired Advanced Medical Optics, manufacturer of the Tecnis Multifocal IOL and the VISX excimer laser.  Visiogen's accommodating IOL, called Synchrony, is designed to deliver improved vision at all distances, potentially eliminating the need for glasses.  Visiogen has obtained he CE Mark.  FDA approval is pending and is expected in mid 2010.  

Steve RubinsteinOptometristSound Shore Vision Care

Alcon, Novartis (Ciba Vision), Astra-Zeneca working on ocular medications?

July 23, 2009

Analysis of:Alcon Signs Agreement With AstraZeneca On Eye Drug Development | www.pharmaceutical-business-review.com

This agreement seems to allow Alcon Laboratories, Inc and Astra-Zeneca  to work together to produce ocular medications. What it doesn't say is that they can also use Ciba Vision's resources in the near future.

Catract Surgery and Premium IOLs

July 19, 2009

Analysis by: GLG Expert Contributor

Analysis of:FDA Approves Alcon's AcrySof® IQ ReSTOR® +3.0 D Intraocular Lens - New Lens Corrects For Cataracts With Presbyopia | www.medicalnewstoday.com

The Alcon ReStor+3 allows an extended range of unaided vision post cataract or clear lens removal. The ReStor+3 model allows a comfortable intermediate reading and distance vision without spectacle correction. . The production ofpremium IOLs promises to increase significantly to the benefit of Alcon, Allergan and B&L.

Gary BarkerPartner/OwnerEYE ASSOCIATES OF WINTER PARK

Welcome addition to our armament, but overuse potential?

July 14, 2009

Analysis of:Bausch and Lomb (BOL) Receives FDA Approval of Besivance(TM), New Topical Ophthalmic Antibacterial for the Treatment of Bacterial Conjunctivitis ('Pink Eye') | www.lifescience-online.com

Potential for overuse and more drug-resistant bacteria

Page : 12345678910Next1 to 10 of 304